A message on the evolution of cancer treatment, Lyell’s commitment to scientific innovation, and how we are working toward our goal of curative cell therapy for any solid tumor.
We have assembled a world-class team, including some of the foremost scientific leaders in the fields of oncology and adoptive cell therapy (ACT).
We are applying Gen-R and Epi-R, our proprietary genetic and epigenetic reprogramming technologies, to overcome two major barriers to successful ACT – T cell exhaustion and lack of durable stemness.
We are developing a multi-modality product pipeline. Each of our programs provides opportunities to expand into additional indications beyond those initially targeted.
Lyell Immunopharma Announces Pricing of Initial Public Offering
Join a team of pioneers courageously striving for ambitious goals: cell therapies that eradicate solid tumors. Let’s do it together.